Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuT-cell receptor gene therapy--ready to go viral?T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection.MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitroTrial Watch: Adoptive cell transfer immunotherapy.Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy.T-cell receptor gene therapy for cancer: the progress to date and future objectives.Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.Challenges in T cell receptor gene therapy.Human leucocyte antigen class I-redirected anti-tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells.Death receptor-independent activation-induced cell death in human melanoma antigen-specific MHC class I-restricted TCR-engineered CD4 T cellsTCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs.T-cell synapse formation depends on antigen recognition but not CD3 interaction: studies with TCR:ζ, a candidate transgene for TCR gene therapy.NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
P2860
Q21131200-486F3DD9-C23C-4601-9195-12E86DF75AD2Q28081611-B8065A0E-CD82-4ED7-8BC6-11B093572575Q33530527-37D7BD64-3108-4DD2-AF7D-FE9254145BD5Q33841127-B27D05FE-59F5-4BB9-B9E5-8F55FF5C4A47Q34050163-EC19B706-3B58-46A4-A29D-DB5CBC003EE5Q36057432-B0F28D1F-1B4F-4C96-B048-E404FA10B374Q36239656-7C9F1A69-F7B7-479E-A753-61290AC716CCQ36909378-B6B36153-C790-47C1-9871-AC2CCF18BC42Q37107843-DE1FAB8A-8AFE-4A98-8A13-4AFA77F2F905Q37275680-BA718284-5237-4E70-83A1-4FA92B50F31DQ38011650-7C24944D-CEEA-4000-B148-3A4173EBF711Q38763198-D86E1710-B70E-4189-A189-F5A4F422CC4AQ39112010-6FE283A3-EC04-4D4B-BBBD-2A2B998BEE6DQ39383424-7FF53C3A-ED9E-4BC2-927A-B47151BD930BQ40043435-7F1B4C98-5F9A-49A5-B14F-88F0AA0D1B9BQ41955439-D39B454D-53E7-4C37-B3A4-21060EC0A6B9Q45869090-B04F611D-217D-480D-86D3-A6BA216064C6Q54945263-F1B5A57D-399D-4616-8610-20C750884C0E
P2860
Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Redirecting human CD4+ T lymph ...... ne transfer requires CD8alpha.
@ast
Redirecting human CD4+ T lymph ...... ne transfer requires CD8alpha.
@en
type
label
Redirecting human CD4+ T lymph ...... ne transfer requires CD8alpha.
@ast
Redirecting human CD4+ T lymph ...... ne transfer requires CD8alpha.
@en
prefLabel
Redirecting human CD4+ T lymph ...... ne transfer requires CD8alpha.
@ast
Redirecting human CD4+ T lymph ...... ne transfer requires CD8alpha.
@en
P2093
P2860
P356
P1433
P1476
Redirecting human CD4+ T lymph ...... ne transfer requires CD8alpha.
@en
P2093
Heuveling M
Ronteltap C
Willemsen R
P2860
P2888
P304
P356
10.1038/SJ.GT.3302388
P577
2005-01-01T00:00:00Z